Bristol Myers: HSR period expires for RayzeBio
As a reminder, the offer is to acquire all outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion.
The expiration of the HSR period removes one of the conditions to the completion of the transaction, which remains subject, among other things, to the contribution of the majority of RayzeBio shares to the tender offer. Unless extended, this period will expire on the evening of February 22.
Copyright (c) 2024 CercleFinance.com. All rights reserved.